Osteonecrosis of the femoral head in sickle cell disease: Prevalence, comorbidities, and surgical outcomes in California

Blood Advances

Volumn 1, Issue 16, 2017, Pages 1287-1295

  Adesina, Oyebimpe ^a,c   Brunson, Ann ^b   Keegan, Theresa H M ^b   Wun, Ted ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85030030695     PISSN: 24739529     EISSN: 24739537     Source Type: Journal    
DOI: 10.1182/bloodadvances.2017005256     Document Type: Article

References (61)

1. Acurio MT, Friedman RJ. Hip arthroplasty in patients with sickle-cell haemoglobinopathy. J Bone Joint Surg Br. 1992;74(3):367-371.
2. da Silva Junior GB, Daher EF, da Rocha FA. Osteoarticular involvement in sickle cell disease. Rev Bras Hematol Hemoter. 2012;34(2):156-164.
3. Poignard A, Flouzat-Lachaniette CH, Amzallag J, Galacteros F, Hernigou P. The natural progression of symptomatic humeral head osteonecrosis in adults with sickle cell disease. J Bone Joint Surg Am. 2012;94(2):156-162.
4. Flouzat-Lachaniete CH, Roussignol X, Poignard A, Mukasa MM, Manicom O, Hernigou P. Multifocal joint osteonecrosis in sickle cell disease. Open Orthop J. 2009;3:32-35.
5. Stoica Z, Dumitrescu D, Popescu M, Gheonea I, Gabor M, Bogdan N. Imaging of avascular necrosis of femoral head: familiar methods and newer trends. Curr Health Sci J. 2009;35(1):23-28.
6. Matos MA, dos Santos Silva LL, Brito Fernandes R, Dias Malheiros C, Pinto da Silva BV. Avascular necrosis of the femoral head in sickle cell disease patients. Ortop Traumatol Rehabil. 2012;14(2):155-160.
7. Adekile AD, Gupta R, Yacoub F, Sinan T, Al-Bloushi M, Haider MZ. Avascular necrosis of the hip in children with sickle cell disease and high Hb F: magnetic resonance imaging findings and influence of alpha-thalassemia trait. Acta Haematol. 2001;105(1):27-31.
8. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23): 1639-1644.
9. Hernigou P, Bachir D, Galacteros F. The natural history of symptomatic osteonecrosis in adults with sickle-cell disease. J Bone Joint Surg Am. 2003; 85-A(3):500-504.
10. Hernigou P, Habibi A, Bachir D, Galacteros F. The natural history of asymptomatic osteonecrosis of the femoral head in adults with sickle cell disease. J Bone Joint Surg Am. 2006;88(12):2565-2572.
11. Aguilar C, Vichinsky E, Neumayr L. Bone and joint disease in sickle cell disease. Hematol Oncol Clin North Am. 2005;19(5):929-941, viii.
12. Kamath AF, Sheth NP, Hosalkar HH, Babatunde OM, Lee GC, Nelson CL. Modern total hip arthroplasty in patients younger than 21 years. J Arthroplasty. 2012;27(3):402-408.
13. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
14. Mullah-Ali DH, Kuo KH, Parmar A, Pasotre YD. A systematic review of the classification, diagnosis, treatment and outcome of osteonecrosis of the hips in sickle cell disease. Blood. 2015;126(23):2069.
15. Neumayr LD, Aguilar C, Earles AN, et al; National Osteonecrosis Trial in Sickle Cell Anemia Study Group. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. J Bone Joint Surg Am. 2006;88(12):2573-2582.
16. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med. 1991;325(21):1476-1481.
17. Osunkwo I. An update on the recent literature on sickle cell bone disease. Curr Opin Endocrinol Diabetes Obes. 2013;20(6):539-546.
18. Patel DV, Sabharwal S. The role of osteotomy in advanced osteonecrosis of the femoral head in sickle-cell disease: a case report. Am J Orthop. 2006; 35(3):125-131.
19. Sanjay BK, Moreau PG. Bipolar hip replacement in sickle cell disease. Int Orthop. 1996;20(4):222-226.
20. Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol. 1996;52(2):103-107.
21. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005; 106(7):2269-2275.
22. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17): 3447-3452.
23. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016; 387(10019):661-670.
24. Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013;128(2):110-116.
25. Beckman MG, Hulihan MM, Byams VR, et al. Public health surveillance of nonmalignant blood disorders. Am J Prev Med. 2014;47(5):664-668.
26. Paulukonis ST, Eckman JR, Snyder AB, et al. Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008. Public Health Rep. 2016;131(2):367-375.
27. Paulukonis ST, Harris WT, Coates TD, et al. Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatr Blood Cancer. 2014;61(12):2271-2276.
28. Wolfson JA, Schrager SM, Coates TD, Kipke MD. Sickle-cell disease in California: a population-based description of emergency department utilization. Pediatr Blood Cancer. 2011;56(3):413-419.
29. Wolfson JA, Schrager SM, Khanna R, Coates TD, Kipke MD. Sickle cell disease in California: sociodemographic predictors of emergency department utilization. Pediatr Blood Cancer. 2012;58(1):66-73.
30. Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res. 1993; (289):136-143.
31. Brunson A, Lei A, Rosenberg AS, White RH, Keegan T, Wun T. Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality [published online ahead of print 3 April 2017]. Br J Haematol. doi:10.1111/bjh.14655.
32. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
33. Charache S, Terrin ML, Moore RD, et al; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
34. Golden C, Styles L, Vichinsky E. Acute chest syndrome and sickle cell disease. Curr Opin Hematol. 1998;5(2):89-92.
35. Vichinsky EP, Neumayr LD, Earles AN, et al; National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865.
36. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B; Cooperative Study of Sickle Cell Disease. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood. 1997;89(5):1787-1792.
37. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. Br J Cancer. 2004;91(7): 1229-1235.
38. Borkar S, Kamble D, Gowler V. Avascular necrosis of left hip joint secondary to sickle cell anaemia for hip arthroplasty. Indian J Anaesth. 2015;59(10): 682-683.
39. Mukisi-Mukaza M, Saint Martin C, Etienne-Julan M, Donkerwolcke M, Burny ME, Burny F. Risk factors and impact of orthopaedic monitoring on the outcome of avascular necrosis of the femoral head in adults with sickle cell disease: 215 patients case study with control group. Orthop Traumatol Surg Res. 2011;97(8):814-820.
40. Mouba JF, Mimbila M, Lentombo LE, Thardin JF, Ondo A. [Avascular necrosis of the femoral head in children with sickle cell disease (Libreville, Gabon)]. Sante. 2011;21(2):89-92.
41. Mahadeo KM, Oyeku S, Taragin B, et al. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. Am J Hematol. 2011;86(9):806-808.
42. Hernigou P, Zilber S, Filippini P, Mathieu G, Poignard A, Galacteros F. Total THA in adult osteonecrosis related to sickle cell disease. Clin Orthop Relat Res. 2008;466(2):300-308.
43. Akinyoola AL, Adediran IA, Asaleye CM. Avascular necrosis of the femoral head in sickle cell disease in Nigeria: a retrospective study. Niger Postgrad Med J. 2007;14(3):217-220.
44. Brown M, Brunson A, Wun T. A method to identify California's sickle-cell disease population and its linkage to the California Cancer Registry. J Registry Manag. 2012;39(2):53-61.
45. Hulihan MM, Feuchtbaum L, Jordan L, et al. State-based surveillance for selected hemoglobinopathies. Genet Med. 2015;17(2):125-130.
46. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512-S521.
47. te Winkel ML, Pieters R, Hop WC, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2011;29(31):4143-4150.
48. Kadan-Lottick NS, Dinu I, Wasilewski-Masker K, et al. Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2008;26(18):3038-3045.
49. Yu T, Campbell T, Ciuffetelli I, et al. Symptomatic avascular necrosis: an understudied risk factor for acute care utilization by patients with SCD. South Med J. 2016;109(9):519-524.
50. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47.
51. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010; 303(13):1288-1294.
52. Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013;381(9870):930-938.
53. Hart A, Bergeron SG, Epure L, Huk O, Zukor D, Antoniou J. Comparison of US and Canadian perioperative outcomes and hospital efficiency after total hip and knee arthroplasty. JAMA Surg. 2015;150(10):990-998.
54. White RH, Garcia M, Sadeghi B, et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010;126(1):61-67.
55. Gardner K, Douiri A, Drasar E, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016;128(10):1436-1438.
56. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014; 89(5):530-535.
57. Dalle Carbonare L, Matte' A, Valenti MT, et al. Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease. Blood. 2015; 126(20):2320-2328.
58. Agarwala S, Shah SB. Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3 years. J Arthroplasty. 2011;26(7): 1128-1134.
59. Cardozo JB, Andrade DM, Santiago MB. The use of bisphosphonate in the treatment of avascular necrosis: a systematic review. Clin Rheumatol. 2008; 27(6):685-688.
60. Luo RB, Lin T, Zhong HM, Yan SG, Wang JA. Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review. Med Sci Monit. 2014;20:2439-2447.
61. Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am. 2007;89(8):1727-1734.